At 8: 30am on May 13th, Yuan Jiajun, former secretary of the provincial party committee, and his party visited the company for investigation. Before the end of the investigation and leaving the company, Secretary Yuan enjoined Chairman Yan Yiyi and General Manager Zhao Chunjian to say, "You should adhere to the talent strategy, strengthen the drive of innovation, and make marine biopharmaceuticals bigger and stronger. Sincere pharmaceutical industry has great hope and great hope! "
Chen Yijun, member of the Standing Committee of the Provincial Party Committee and Secretary-General, and Liu Xiaotao, member of the Standing Committee of the Provincial Party Committee and secretary of Wenzhou Municipal Party Committee accompanied the investigation.
At 4: 30 pm on March 23rd, Governor Wang Hao and his party visited the company for investigation. In the investigation, Governor Wang told Chairman Yan Yiyi that to do business, we should not only dare to be the first and be innovative, but also be down-to-earth and practice hard. It is necessary to closely integrate the development of enterprises with the prosperity of the country, the prosperity of the nation and the happiness of the people, bravely assume social responsibilities, and drive the region and the masses to achieve common prosperity.
During the year, the main leaders of the provincial party committee and the provincial government both visited the company for inspection and investigation, which encouraged and spurred all the cadres and employees of the company. party member and employees expressed their desire to become bigger and stronger closely around marine biomedicine and live up to the entrustment of the leaders.
On April 25th, the company held the 18th meeting of the 3rd Board of Directors and the 15th meeting of the 3rd Board of Supervisors respectively. The 2021 annual general meeting of shareholders was held on May 16th, and the members of the fourth board of directors and the fourth board of supervisors were elected. Among them, Yan Yiyi, Zhao Chunjian, Ren Bingjun, Qiu Kerong and Ke Zehui were elected as directors; Zeng Huanqun and Kong Jianyi were elected as supervisors.
After three rounds of "direct elections", on August 27th, the Party Committee of Chengyi Pharmaceutical held a plenary meeting of general party membership meeting to elect the members of the fifth Party Committee. Comrade Zhao Chunjian was elected as Party Secretary, Comrade Lu Zhidong as Deputy Secretary, and three comrades Lu Sunzhan, Ke Zehui and Fu Bangwu as Party members.
In his speech, Secretary Zhao Chunjian said that the new Party Committee will perform its duties in its new post, be honest and set an example, and continue to lead the party member and cadres and workers of the company to inherit the good traditions, inherit the good experience and carry forward the good work style, so as to continue to strive for the high-quality development of the company.
After the 20th National Congress of the Communist Party of China was held, the Party Committee of the Company quickly set off a climax of studying and implementing the spirit of the 20th National Congress, and made great efforts to put the new spirit, new deployment and new ideas in Report to the 20th CPC National Congress into practice, so as to make greater contributions to the high-quality development of the Company and the construction of a "sea garden" for common prosperity.
Comrade Fu Bangwu is an advanced model worker trained and forged by Chengyi Pharmaceutical, and also a typical epitome of the spirit of "diligence, rigor, innovation and dedication" of hundreds of craftsmen in the company. He won the "National May 1 Labor Medal" this year and went to Hangzhou to receive the award. The company held a welcoming ceremony.
On the afternoon of April 28th, the company held a joint meeting of the Party, government and labor groups, attended by more than 30 middle and senior managers, and listened to the report on the deeds of Comrade Fu Bangwu.
In his speech, Chairman Yan Yiyi emphasized that we should learn from model workers, strive to be craftsmen, make concerted efforts and work hard to jointly promote the high-quality development of Sincere Pharmaceutical.
After the successful introduction of traditional Chinese medicine decoction piece "Dendrobium officinale powder", Chengyi Pharmaceutical entered the "big health industry" in 2022, which can be described as "everything is ready": on August 17th, the company's "fish oil soft capsule health food" passed the on-site inspection of the production license of Zhejiang Market Supervision Administration, and on August 24th, it obtained the first "health food production license" in Wenzhou, becoming the first health food production enterprise in Wenzhou, producing health food for Wenzhou. After the National Day, the company's 0.5g "Sankang brand" and 1g "Wasepa brand" two specifications, the content of which is more than 93%, were successfully approved. On December 29th, the first batch of 5025 high-purity fish oil soft capsule health food was successfully listed.
In addition, the trial production of "nervonic acid" health food to maintain the heart and brain health of middle-aged and elderly people has been successful. The "sincerity section" of "big health industry" has quietly taken shape.
It is the key period for the company to make great strides from "generic drug stage" to "innovative drug stage". At the personal invitation of Chairman Yan Yiyi, on the afternoon of September 19th, Academician Ding Jian of China Academy of Engineering and researchers Zhang Haiyan and Huang Chenggang from Shanghai Institute of Pharmacy of China Academy of Sciences visited the Zhejiang headquarters of Chengxin Pharmaceutical Co., Ltd. to give special technical guidance on the company's "research and innovation project". Academician Ding Jian said that since the outbreak, many domestic enterprises have been greatly impacted, but Chengxin Pharmaceutical has been moving upward, which shows that the products are excellent and the market is rigid.
During the year, Li Xiaojian, academician of China Academy of Engineering and president of Wenzhou Medical University, Zhang Genming, director of the Provincial Market Supervision Bureau, Chen Kui, deputy director of the Provincial Food and Drug Administration, and other drug supervision system experts led a team to visit the company to guide the investigation and put forward valuable opinions for the company's product research and development and market expansion.
On August 26th, the company successfully signed a contract with the Asian Research Institute of the province to strengthen the development of a series of products, such as health care capsules, medicinal liquor, medicinal tea and so on.
According to researcher Chai Yiqiu, the leader of entomogenous fungi in Zhejiang Asia Institute, "Cordyceps Cicadae" is known as "Cordyceps sinensis" in the south, with a medicinal record of 1,500 years, 800 years earlier than Cordyceps sinensis. Cicadae has the effects of improving immunity, improving eyesight and protecting liver, resisting renal failure, relieving pain, calming down, resisting tumor and lowering blood sugar and blood pressure. The provincial Asian Research Institute has made great breakthroughs in the fields of artificial cultivation, pharmacological research and functional product development of Cordyceps cicadae, and selected and approved a new variety of Cordyceps cicadae No.1 for the first time in the world. By the end of the year, Chengyi Pharmaceutical Co., Ltd. is speeding up its efforts, hoping to bring the "Cordyceps Cicadae" series products to the market as soon as possible.
The company's flagship product, Glucosamine Hydrochloride Capsules for the treatment of systemic osteoarthritis, has unique advantages such as "no excipients, high purity, excellent quality, full specifications, and industrial chain". In 2020, it won the bid as the first in the third batch of national centralized procurement, with a clinical market share of over 42%.
On the afternoon of June 16th, General Manager Zhao Chunjian of the company signed a contract with General Manager Ma Yunpeng of McKen Pharmaceutical (Dalian) Co., Ltd. in Dongtou. The plan is to achieve a sales volume of over 5 billion ammonia sugar capsules in the next decade, creating a leading brand in the ammonia sugar OTC (over-the-counter drug) category market. Sincere Pharmaceutical specifically handed over 0.48 grams of ammonia sugar series to McKen for operation, achieving strong cooperation.
On July 23rd, the brand new packaging design of "Virgo" ammonia sugar "0.48 grams × The launch ceremony of the national sales market of "24 capsules/box" was held at the Dongtou Manufacturing Department, bringing together product promotion service providers from all over the country. The newly launched "0.48 grams × 24 capsules/box "of ammonia sugar capsules pursue a sporty and youthful consumption style, with an 8-day oral dose to assist in joint health and exercise wellness.
On December 20th, at the launch ceremony of "Yingyangji" in Kunming, Yunnan, the new packaging "0.48 grams × 90 capsules/bottle of ammonia sugar has been launched in Kunming, and will further expand the brand promotion of Sincere Pharmaceutical's ammonia sugar through the effect of CCTV advertising.
In June 2021, the company acquired 106 acres of land and started the second phase of construction. The second phase of the "Health Industry Park" focuses on marine biopharmaceuticals, traditional Chinese medicine, and other areas of development, radiating and driving the transformation and upgrading of the health industry in Dongtou as a national marine economic development demonstration zone. The project includes the construction of three fish oil extraction workshops, one traditional Chinese medicine extraction workshop, one traditional Chinese medicine decoction workshop, two Class C warehouses, tank farms, power centers, and expert buildings, with a total investment of approximately 1 billion yuan.
During the year, the provincial key construction project - the EPA and traditional Chinese medicine project with an annual output of 1000 tons of super fish oil - was awarded the "Top 10 Private Investment Projects in Wenzhou City in 2021" at the high-quality development conference of the city's manufacturing industry and private economy. At present, the civil engineering project has been completed, and the equipment installation in the fish oil workshop has been completed simultaneously. Trial production will be launched within the year.
Meanwhile, the company's "landscape pool" was completed and put into use on May 1st. "Landscape pool" takes "one dragon pillar" as the center, reflecting the firm confidence and pillar of sincere people to run a good enterprise; Taking the "two big vats" of the initial stage of enterprise establishment as the two basic points, the sincere spirit of "diligence, frugality, rigor, innovation, and dedication" is reproduced, demonstrating the firm belief of sincere people to "always follow the Party".
On October 24th, 2022, Zhejiang Economic and Information Department, Ecological Environment Department and Emergency Management Department jointly issued the Notice on Promulgating Key Monitoring Points of Chemical Industry in Zhejiang Province in 2022 (Zhejiang Economic and Information Materials  No.205), which clearly listed Chengxin Pharmaceutical as "the first batch of key monitoring points of chemical industry in Zhejiang Province" and was the only one in Wenzhou, which laid a solid foundation for the company's future projects and long-term development.
At the beginning of the year, the company invested more than 6 million yuan to upgrade the waste gas treatment system and built the "organic waste gas treatment and heat storage high temperature oxidation furnace" (RTO system for short). Its "organic waste gas" treatment effect is over 98%, the heat recovery efficiency is over 95%, and the technical level is leading in China. The project was rated as a Wenzhou municipal environmental protection science and technology demonstration project.
At the same time, the company invested more than 1 million yuan to build a "smart energy management system", which adopts automation, informationization, visualization and centralized management mode to monitor and analyze the energy consumption of each workshop in real time, find out problems in time, find out the energy-saving potential, define the energy-saving direction, realize dynamic monitoring and digital management, and provide a strong guarantee for the company to realize energy saving and green development.
During the year, the company's stock had seven daily limit, namely: January 19th, February 23rd, March 11th, April 18th, August 8th, November 30th and December 15th, which brought great profits to investors. This is a comprehensive response that the company's high-quality development is recognized and favored by investors, and it is also a comprehensive response that the company constantly improves the quality of information disclosure and creates a good investment environment; Strengthen the management of the "three meetings" and carry out good results of corporate governance in accordance with the law. The company also held various forms of investor exchange meetings, online and offline performance briefings in Shanghai and other places to welcome investors to come to Dongtou headquarters to inspect enterprises on the spot, constantly enhancing the transparency of enterprises and enhancing investor confidence.
As all parts of the country enter the "new stage of epidemic prevention and control", the demand for anti-virus drugs in all parts of the country has increased sharply. The company's measures of working overtime to produce drugs and anti-epidemic materials to ensure market supply have been continuously broadcast on CCTV programs such as "Chao Wen Tian Xia", "News 30 Minutes" and "News Network" since December 20, conveying the positive energy of the company's initiative to assume social responsibility.
To celebrate the 100th anniversary of the founding of the Party, the Party Committee of the Company took the lead in organizing and holding a series of celebration activities: On the evening of May 29th, the "Red Classic Theme Song Club" jointly organized by the Party and Government Workers' Corps of the Company kicked off-28 programs selected by the workshops, departments and Shanghai's three major centers were staged in turn; On the afternoon of June 26th, the celebration meeting of the centenary of the founding of the Party was held: the secretary of the Party Committee delivered a speech, party member took the oath on the stage, and commended 10 old party member who had been in the Party for 30 years. The meeting ended with the singing of "We Walk on the Road" by all the staff.
In order to inherit the Red Gene and listen to the voices of the masses, the Party Committee organized more than 100 party member and middle and senior managers to visit the families of 100 front-line employees within 100 days. During the year, one party member was commended by the District Committee, two branch secretaries were awarded as "red-collar talents" in Dongtou District, one party member was hired as "innovation expert of Wenzhou science and technology think tank", and party member and general manager Zhao Chunjian were awarded as "outstanding entrepreneurs in Wenzhou in 2020". A large number of party member comrades have made contributions in ordinary posts, boosting the high-quality development of enterprises.
On March 24, the Wenzhou Municipal Party Committee and the Wenzhou Municipal Government announced and commended a group of "advanced collectives and exemplary individual to promote high-quality development in Wenzhou", and the company won the title of advanced collectives.
In 2020, the company achieved revenue of 758 million yuan, net profit of 165 million yuan, and tax payment of 73 million yuan. The company has more than 20 new products under research, of which 1 variety has completed clinical trials, 3 product specifications have passed consistency evaluation, and the main product, glucosamine hydrochloride capsules, has won the bid for the first national centralized procurement, winning over 41% of the national clinical medical market share. We have accumulated 13 invention patents and 21 utility model patents. The enterprise pharmaceutical research and innovation team has been successfully selected for the "Wenzhou Major Talent Project" and has been selected as a high-level innovation team in the field of enterprise technology.
On September 15th, Yao Gaoyuan, Deputy Secretary of the Municipal Party Committee and Mayor, and a delegation came to the company to investigate the marine economy. They requested the company to leverage the advantages of leading enterprises, deeply utilize the unique resources of local marine organisms, and enhance industry competitiveness. On the morning of November 26th, the new leadership of the district committee, including Guo Yunqiang, the secretary of the district committee, and He Liping, the deputy secretary, visited Yan Dong, a meritorious entrepreneur, and pointed out that Sincere Pharmaceutical is an important support for the development of the marine economy in Dongtou, with unlimited development potential. The company needs to make greater efforts to expand and strengthen the enterprise, and strive to set industry benchmarks.
During the "Ten Three Five" period, the company successfully went public on the main board and entered the top 100 companies in Wenzhou. Its headquarters were located in Shanghai, and an industrial park was built to accelerate enterprise cloud deployment and achieve green development. Over the past five years, the company achieved revenue of 2.392 billion yuan, an increase of 104%, net profit of 530 million yuan, an increase of 138%, and tax revenue of 326 million yuan, an increase of 87%. In order to achieve long-term and comprehensive layout, the company has organized the preparation of the "Ten Four Five" Development Plan, which clarifies that "Ten Four Five" closely revolves around the three major development directions of "marine pharmaceuticals, biopharmaceuticals, and traditional Chinese medicine" and the double hundred goal of "a hundred billion market value, a century old enterprise", to seize the strategic high point and achieve the company's collectivization and high-quality development. According to the 2021 third quarter report, the company achieved significant year-on-year growth in revenue and net profit, ushering in a "good start" in the opening year of the 14th Five Year Plan.
In the first half of the year, the news that Chengyi Pharmaceutical will start construction of "Marine Biomedical Manufacturing Project" has aroused widespread concern from all walks of life. On June 16th, Beijing's "Beijing News" reported that the marine biomedical manufacturing project invested by Sincere Pharmaceutical Co., Ltd. with 670 million yuan as its main development direction is an area that the state will focus on encouraging and supporting for a long time. Among them, the highlight is the EPA construction project of ultra-high purity fish oil. Its implementation will take Dongtou as a national marine economic development demonstration zone to transform and upgrade the health industry, which is also conducive to the company's long-term development.
On the morning of November 12th, the company's workshop with an annual output of 1,000 tons of ultra-high purity EPA fish oil started construction for three months, which fully reflected the "sincere speed".
The marine biomedical manufacturing project of Chengyi Pharmaceutical Co., Ltd., namely the second phase of "Healthy Industrial Park", covers an area of 106 mu, with a construction area of about 80,000 square meters, with a total investment of 670 million yuan. It is constructed, developed and produced according to the current domestic standards of "fastest speed, largest scale, highest quality and best price" and the integrated whole industrial chain of fish oil raw materials and preparations. At present, the company has completed the pilot test of EPA (Ethyl Eicosapentaenoic Acid) soft capsules, with an EPA content of over 98%, which can effectively prevent and treat cardiovascular and cerebrovascular diseases.
According to the overall deployment of the company, the company will focus on the implementation of the strategy of "two strong and one big" during the 14th Five-Year Plan period-to strengthen the ammonia sugar industry and fish oil industry, to be a greatly healthy industry, and strive to achieve a per capita industrial added value of over 2 million yuan (currently 1.68 million yuan) and a per capita monthly income of over 10,000 yuan (currently about 7,000 yuan) during the 14th Five-Year Plan period. Therefore, on October 28th, the company established Guangzhou Sandaoyuan Pharmaceutical Technology Co., Ltd. with a registered capital of 10 million yuan, and acquired two Chinese medicine companies, namely, Yunnan Huzhimeng and Luxi Yikang. Focusing on Guangzhou and Yunnan, the company deployed the development and sales of big health foods, health products and medicines, and planned to expand the "big health section" on the basis of successfully launching the Chinese medicine variety "Danyining" and the innovative Chinese medicine "Traditional Chinese Medicine Dry Decoction".
On January 19th, the company reached a cooperation with Shanghai Ruijin Hospital, a well-known domestic hospital, to jointly develop a pancreatic duct bracket, a cross-shaped irrigation drainage tube and a new drainage irrigation tube. The industrialization of these three patents is of great significance for reducing the incidence of pancreatic fistula and improving the success rate of pancreatic surgery in the future. Shanghai Ruicheng Biomedical Technology Co., Ltd., a subsidiary of the company, was established on February 1, 2021 with a registered capital of 5.6 million yuan, which indicates that Chengyi Pharmaceutical has taken an important step in the field of medical devices.
Actively participated in the evaluation activities of the 2021 Wenzhou Mayor Quality Award, and made outstanding achievements in strategic formulation, quality control, market service, resource integration and process management, and was awarded the "Wenzhou Mayor Quality Award" (shortlist). In recent years, in order to guide the company to pursue the extraordinary, improve the quality of products, services and operations, and enhance its competitive advantage, the company actively introduced the extraordinary performance model to continuously improve the management maturity of the company, and successively won the Dongtou County Quality Award in 2012 and the Wenzhou Quality Management Innovation Award in 2019, forming and applying the "product life-cycle standardization+digital quality control model" to promote the transformation of the pharmaceutical industry to digitalization, networking and intelligence. The goal of drug quality control has been achieved, such as standardization of enterprise management, visualization of production process, digitalization of equipment operation, refinement of material consumption, automation of environmental monitoring and integration of information, which provides a model for China pharmaceutical industry and other manufacturing industries to learn from.
Starting from the four latitudes of "beauty of production, beauty of innovation, beauty of humanity and beauty of environment", the company pays special attention to the construction of automatic, digital and intelligent demonstration workshops, the construction of provincial enterprise technology centers and provincial medical and health research institutes, the construction of corporate culture and the construction of production environment, thus being rated as "the first batch of most beautiful factories" in Wenzhou. In 2021, the company once again advanced into the ranks of "Top 100 Comprehensive Enterprises in Wenzhou" and "Top 50 Manufacturing Enterprises". The above awards are inseparable from management innovation.
On November 10th, two specifications of torasemide injection (2ml:10mg, 4ml:20mg) developed and produced by the company passed the conformity evaluation of national generic drugs, which was the first similar product in China. With the strong east wind of "over-evaluation", on November 15th, the company signed a contract with Nanjing Newgranville Biotechnology Co., Ltd. to actively expand the "three-year plan" of torasemide injection market in China, and it is planned to strive to increase its sales volume by 100% in the next three years, so as to remain the first in the national market. At the beginning of December, ornithine aspartate injection produced by the company obtained the Drug Registration Certificate approved and issued by National Medical Products Administration.
During the year, the company's drug registration and clinical research work was promoted in an orderly manner. By the end of the year, the company has more than 20 new products under research; One of them has completed clinical trials; Two APIs have been declared and accepted, and four varieties have been successfully approved; There are 8 varieties of oral solid preparations and 15 small-volume injections in the process of evaluating the consistency of generic drugs.
On March 9th, the small capacity injection workshop (i.e. Workshop 105) of the company's new formulation building passed the GMP compliance inspection of the Zhejiang Provincial Drug Administration. The workshop 105 inspected had non final sterilization production lines and final sterilization production lines, with a total investment of 96.588 million yuan. The GMP compliance inspection in Workshop 105 is beneficial for the company to continue ensuring product quality and stable production capacity, and has a positive impact on the company's future development.
On April 9th, the mask workshop (301 workshop) successfully passed the registration inspection and obtained a medical device production license. The disposable medical masks produced by the mask workshop were officially approved for listing, which is conducive to the company entering the medical device sector and creating new profit growth points. The company has undergone 17 domestic and foreign regulations and customer audits throughout the year, and key export products such as azathioprine and thioprine have successfully passed audits.
In recent years, the company has vigorously promoted digital transformation, built management systems such as ERP, OA office and online shopping mall, and an advanced "intelligent factory" with automation, informationization, intelligence and standardization that can be visited all the time in China. It has been rated as "Shangyun Benchmark Enterprise in Zhejiang Province" and Wenzhou City's integration demonstration enterprise.
In 2021, actively participated in the construction of the "black box" system for drug safety supervision in the province, completed the second phase of the ERP management system, and took the lead in launching the construction of the "smart energy" management system in the city. It collected, monitored, and analyzed all energy data scattered in various production areas in real time, achieving smart supervision and promoting energy conservation and consumption reduction. On December 14th, the Wenzhou Municipal Bureau of Economy and Information Technology announced a list of 44 intelligent factories (digital workshops) in the city, making it one of the top pharmaceutical companies in the city. At the same time, it was rated as the "2021 Provincial New Generation Information Technology and Manufacturing Integration Development Pilot Demonstration Enterprise".
On the morning of March 22nd, the company held a "Charity Day Donation" donation ceremony at the R&D building square. According to statistics, the company donated 300000 yuan to the Dongtou District Charity Association on that day; Individual donations from employees amounted to 40195 yuan. The company has donated a total of 14.49 million yuan over the years and was awarded the "Wenzhou Charity Award" Advanced Collective in 2021.
The company has carried out military support and condolences for 20 consecutive years, promoting the red gene; Actively assume tax responsibility and adhere to the legal and compliant operation of "one book"; Adhering to annual dividend distribution to shareholders, the company has accumulated a dividend of over 370 million yuan. During the year, the company increased the average salary of all employees by 10%, benefiting all employees with development dividends. The company also continues to carry out the construction of a "clean and honest enterprise", with the chairman and general manager taking the lead in signing the "Clean and Self disciplined Commitment Letter", guiding the spirit of clean governance to every field, every front, and every employee of the company.
On January 27, the company organized employees to work overtime to produce antiviral drugs to help the key epidemic areas in Wuhan, and CCTV, Xinhuanet and other mainstream media reported in succession.
The company donated more than 1 million yuan in cash and medicine for epidemic prevention and treatment to Hubei Red Cross Society and Zhejiang Charity Federation.
On March 17th, the high-quality development conference of the province's manufacturing industry was held in the form of video.
Chen Weijun (first in the front row), member of the Standing Committee of the Provincial Party Committee and secretary of Wenzhou Municipal Party Committee, announced at the conference by video: Sincere Pharmaceutical Health Industrial Park and Marine Biomedical Manufacturing Project are officially put into production!
On May 19-22, the oral solid preparation workshop (workshop 106) of the company's new preparation building successfully passed the GMP compliance inspection.
In December, the company's KN95 mask passed the SGS full inspection and passed.
On May 21st, the company announced the acquisition of part of the equity of Kangle Pharmaceutical.
On March 19th, the company issued a notice saying that Antang Capsule was the first to pass the consistency evaluation.
On August 20th, the company participated in the national centralized procurement of ammonia sugar capsules and won the bid in the first place, accounting for 41% of the national medical market share.
On November 10th, the inaugural ceremony of Chengyi Pharmaceutical's ammonia sugar capsules, a winning product from Jicai, was held.
On May 8, the Provincial Department of Ecology and Environment organized an expert review and passed the first phase environmental assessment of the Health Industrial Park.
On September 24th, the company took the lead in obtaining the safety production license (factory-wide certification).
In recent years, the company has invested more than 60 million yuan in the construction and renovation of safety and environmental protection facilities. The picture shows the construction site of the company's No.2 boiler low-nitrogen renovation on August 26.
On October 16th, the opening ceremony of the joint education between China Pharmaceutical University and Chengyi Pharmaceutical was held. The picture shows a group photo of guests and students.
The company's "technology innovation team" held a seminar on new drug research and development strategy.
On April 27th, the company announced the profit distribution plan. In the three years since listing, the accumulated dividend has reached 120 million yuan.
On July 18th, the company held a semi-annual production and operation meeting in Fujian Huakang Pharmaceutical Co., Ltd. to sum up experience and plan the production and operation tasks for the second half of the year.
On October 29th, the company released the third quarterly report.
On December 10th, the company and Innovation Tongheng held the signing ceremony of "EPA production line construction project with an annual output of 100 tons of high-purity fish oil".
In mid-December, the conceptual design of the second phase of Health Industrial Park was completed.
Listed as one of the 12 "Best Market Value Management Listed Companies" in China.
In 2017, the company's net profit was 69.23 million yuan. In order to achieve rapid and sustainable growth of profits, market value management is one of the important securities affairs of listed companies.
On the afternoon of October 26, 2018 (Friday), the company announced that in the first three quarters, it achieved a total operating income of 400 million yuan, a year-on-year increase of 76.21%; The net profit after deducting non-profit was 70.7173 million yuan, a year-on-year increase of 71.01%. The company's earnings per share is 0.84 yuan. To this end, the company plans to transfer 4 shares for every 10 shares, which is the first "high transfer" implemented by the company.
Affected by this good news, at 9: 30 am on Monday, October 29, as soon as the Shanghai and Shenzhen stock markets opened, the company's share price was firmly sealed on the one-word daily limit of 27.61 yuan. This is the third daily limit of the company's share price during the year.
On December 8th, at the 13th conference of "Investigation and Selection of Competitiveness and Public Trust of Listed Companies in China", the jury evaluated Sincere Pharmaceutical as "the best listed company with market value management" according to the comprehensive indicators of the maintenance, management and promotion of stock market value by enterprises. Ke Zehui, the company's deputy general manager and secretary-general, attended the award.
In 2017, the "comprehensive financial competitiveness" ranked first in Wenzhou manufacturing listed companies and 18th in Zhejiang.
Financial competitiveness is one of the core competencies of listed companies. The 21 indicators of the five major competencies "profitability", "growth and capital accumulation capabilities", "operating capabilities", "solvency" and "cash earning capabilities" are the criteria for judging the level of financial comprehensive competitiveness.
In 2017, what is the comprehensive financial competitiveness of 17 Wenzhou manufacturing companies listed on A-shares?
The Wenzhou investigation team of the National Bureau of Statistics conducted an investigation, analysis and evaluation of 21 indicators. The comprehensive financial competitiveness of Chengxin Pharmaceutical ranked first among 17 Wenzhou manufacturing companies listed on A-shares and 18th among 322 manufacturing companies in the province.
The "1+X" development model of "headquarters leadership" stands out.
On January 15th, 2018, the company established overseas business department, and registered its wholly-owned subsidiary-Canada Sage Herb Biotechnology Co., Ltd. in Canada to develop a new dosage form of traditional Chinese medicine-"dry decoction", as well as engage in the international market development of chemical raw materials and the introduction of new international preparations and technologies.
On June 19th, the company's marketing center, technology development center and securities affairs center settled in Shanghai "Dahongqiao", realizing the platform leap from the sea to Shanghai.
In November, the company completed the "first order" of M&A after listing, and incorporated Fujian Huakang Pharmaceutical Co., Ltd.
Together with Jiangsu Chengyi Pharmaceutical's wholly-owned subsidiary and Dongtou Small Loan Company, Chengyi Pharmaceutical has formed a "1+5" layout for major cities in the Yangtze River Delta and overseas development. A production model of "front shop and back factory" and a development model of "headquarters leadership" stand out.
"High-quality development demonstration enterprise" settled in Cheng Yi
On the afternoon of August 6th, Zhao Chunjian, vice chairman and general manager of the company, attended the "Wenzhou Opening-up Conference" held by the municipal party committee and municipal government, and Chen Weijun, vice governor and secretary of the Wenzhou municipal party committee, delivered an important speech. At this conference, the company won the "Wenzhou High-quality Development Demonstration Enterprise" award, and General Manager Ren Bingjun won the title of outstanding entrepreneur in Wenzhou in 2017.
On the afternoon of November 29th, Zhao Chunjian attended the Dongtou District Quality Development Conference and gave a typical speech. Zhao Chunjian stated that the company will adhere to the bottom line, strengthen responsibility, ensure the production of conscientious drugs, sell reassuring drugs, and accelerate the high-quality development of the enterprise.
Launch of the "One Station, Two Institutes" Research development System
In March 2018, the company established the first "Academician Expert Workstation" in Dongtou, and cooperated with Ding Jian, an academician of China Academy of Engineering, focusing on the research and development of new anti-tumor drugs; In December of that year, the station was named "Wenzhou Academician Expert Workstation".
In May 2018, the company established the "New Drug Research Institute" in cooperation with the team of Li Xiaoyun, the president of Wenzhou Medical University, and devoted itself to the research and development of new drugs.
Since "Chengyi Pharmaceutical Great Health Research Institute" was recognized as Zhejiang Provincial Enterprise Research Institute in August 2017, the company established the organizational structure of a great health research institute with four departments and eight departments in 2018.
Since the establishment of the Research development system of "one station, two institutes", the company has continuously recruited scientists, professors and scholars as the core members of the Research development team, and held new product selection meetings, innovative Chinese medicine product review meetings and new product negotiation meetings in Shanghai and other places to agree on major strategic topics, thus "setting the tone" for the company's "big health" products and achieving phased results.
Ribavirin won the gold medal in Zhejiang patent.
On January 19th, at the provincial conference on scientific and technological innovation and intellectual property rights in 2018, the "chemical synthesis method of ribavirin condensate" declared by the company won the "Zhejiang Patent Gold Award" issued by the Science and Technology Department of Zhejiang Province and the Provincial Intellectual Property Office. There were only 15 gold-winning units in the province, and Lv Zhidong, the company's quality director, attended the awarding ceremony. Previously, the patent was awarded the Excellence Award by China Petroleum and Chemical Industry Federation.
In addition, five products, ribavirin, azathioprine, torasemide injection, glucosamine hydrochloride and glucosamine hydrochloride capsules, were rated as outstanding industrial products in Zhejiang Province in 2018.
Non-net profit increased by 71% in the first three quarters.
On October 26, the company released its report for the third quarter of 2018. The report predicts that the operating income in the first three quarters of 2018 will reach 400 million yuan, up 76.21% year-on-year, and the net profit attributable to shareholders of listed companies will reach 71.18 million yuan, up 56.03% year-on-year. The non-net profit attributable to shareholders of listed companies was 70.72 million yuan, a year-on-year increase of 71.01%.
The main reasons for the increase in performance are: since the first three quarters, the company has strengthened the sales of key pharmaceutical products, increased the marketing assessment and incentive mechanism of key products, and continuously adjusted the sales model of preparations, which has led to the increase in sales of joint products, vitamins and other pharmaceutical products, which has significantly improved the company's performance.
13 Central Media Joint Interviews with Chairman.
At the beginning of May, Dongtou District Party Committee and District Government rated Dongtou's "15 Most Influential Events" and "Chengyi Pharmaceutical's Main Board Listed, Wenzhou Pharmaceutical's First Stock Born" as "Major Events" in the past 15 years.
To this end, on the morning of May 7, 13 well-known media reporters from China, including Xinhuanet, People's Daily and Zhongxin.com, came to the company for a special interview on marine economy, and Chairman Yan Yiyi accepted a joint interview with the interview group.
Cultivate new kinetic energy and enter a new era.
On January 5th, Ren Bingjun, General Manager, attended the "On-site Promotion Meeting of New Kinetic Energy Cultivation and Transformation and Upgrading of Traditional Manufacturing Industry in the City" and made a typical speech. Zhou Jiangyong, member of the Standing Committee of the Provincial Party Committee and former secretary of Wenzhou Municipal Committee, delivered an important speech.
On October 16th, Zhao Chunjian, vice chairman and deputy general manager, as a representative of Wenzhou pharmaceutical manufacturing industry, was cordially received by Che Jun, secretary of Zhejiang Provincial Party Committee, and attended a symposium of Wenzhou private entrepreneurs.
On November 8, Zhao Chunjian was cordially received by You Quan, Secretary of the Secretariat of the CPC Central Committee and Minister of the United Front Work Department of the Central Committee, and attended the Wenzhou Private Entrepreneur Symposium.
On November 9, Zhao Chunjian attended the 2018 World Wenzhou People's Congress on behalf of Dongtou business community.
Strive to build an island model of "two healthy" development
On the morning of March 15th, the company held a grand celebration of the first anniversary of the listing of the main board in the 50th anniversary square. In the afternoon, a symposium on promoting the development of "two healths" (healthy development of private enterprises and healthy growth of business people) was held in the company led by Shi Aizhu, member of the Standing Committee of Wenzhou Municipal Committee and Minister of United Front Work of Municipal Committee. The leaders attending the meeting praised Yan Yiyi, the chairman, for witnessing the whole process of 40 years of reform and opening up since he became the factory director in 1980, and for listing a small pharmaceutical factory belonging to an island army family.
On the afternoon of July 6th, Zhu Rongshua, deputy director of the United Front Work Department of the Municipal Party Committee and secretary of the Party Committee of the Municipal Federation of Industry and Commerce, convened entrepreneurs from Dongtou District to hold a consultation meeting in the company on the policy formulation of establishing "two healthy" development pioneer areas in Wenzhou.
On October 17th, Zhao Chunjian, vice-chairman and deputy general manager, represented Dongtou industrial and commercial circles to attend the conference of creating "two healths" pioneer zone in Wenzhou in the new era.
Construction of Chengyi Pharmaceutical Health Industrial Park and Participation in "Wenzhou Challenge Six Competitions"
The "Health Industrial Park", which started construction on January 10th, has a total investment of nearly 500 million yuan, of which the equipment investment of the preparation building is more than 200 million yuan. It will be an automatic, informative, intelligent and standardized preparation production base that can be visited all the time, including the production of small-capacity injections, freeze-dried powder injections, capsules, tablets, powder oral preparations and other products with various varieties, dosage forms and specifications, so that the annual production capacity of the company's preparation products will reach more than 1 billion yuan.
The "Healthy Industrial Park" has a construction area of 60,000 square meters, and it took only about 10 months from the start of construction to the basic completion, which fully embodies the "sincere speed". At present, it is participating in the "Six Competitions" organized by the Municipal Party Committee and the Municipal Government, which is one of the model projects of "kinetic energy conversion" in the city.
The company deployed to create a "clean enterprise"
In August, the company took the lead in creating an "incorruptible enterprise" in the whole region. Chairman Yan Yiyi made four arrangements for the "creation" work: first, we should improve various systems, and "incorruptible" stipulates that documents, agreements and contracts should be entered; Second, the company should "sunshine everywhere, leaving no dead ends"; Third, the "integrity" rule should be extended to all fields of the company; Fourth, party member cadres should give full play to the spirit of daring to take responsibility.
In September, the Party Committee of the Company completed the general election of five Party branches, elected new branch committees, and implemented the spirit of "Dare to take responsibility and be brave in dedication" to the new branch committees.
In order to carry forward the fine traditional culture, at the end of the year, the Party Committee of the company issued two "initiatives" in succession: on December 19th, the Party Committee of the company issued a document asking the cadres above the middle level and members of all branches of the company to use domestic brand mobile phones during working hours; On December 24th, the Party Committee of the company issued a document asking party member cadres not to celebrate "foreign festivals". Yan Yiyi, Chairman of the Board of Directors, took the lead in celebrating the "Great Man's Day" in Shanghai Company, and held activities in memory of Comrade Mao Zedong.
Enterprises are on the cloud side, and companies are equipped with "wisdom brains"
On the morning of January 17th, the company's ERP system (Phase I) was officially put into operation. After the ERP project is completed, the enterprise will be promoted to the "cloud" end, and the operation management system will create an open smart factory model, realize mobile orders and "cloud" office, open up the upstream and downstream information of the company, improve management efficiency, and promote the organic integration of industrialization and informatization.
By December 1st, the company started OA collaborative office system. Through the implementation of Inspur ERP system integrating human resources, sales, procurement, inventory, cost and finance, the management level of enterprises has been improved, the response speed of enterprises to the market has been accelerated, and the competitiveness of enterprises has been enhanced.
The "Cheng Yi" high-speed passenger ship sets sail
On the morning of July 18th, Dongtou District Party Committee and District Government held the "Title and maiden voyage ceremony of Chengxin and Huazhong", and Zhao Chunjian, vice chairman and deputy general manager, signed a contract with the subsidiary company of Dongtou District Transportation Bureau on behalf of the company. The opening of the "Sincerity" high-speed passenger ship, which is exclusively sponsored by the company, provides convenient transportation for people on outlying islands such as Dongtou Yuanjue, Luxi and Damen, which is also a manifestation of the company's social responsibility.
Subsequently, 13 employee representatives, led by Qiu Kerong, general manager of Dongtou Manufacturing Department, boarded the maiden voyage "Sincerity" and followed the passenger ship to experience the high-speed trip at sea.